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 ABSTRACT 
 
 
The polymorphic merozoite surface protein (MSP-1) of Plasmodium falciparum is a major 
asexual blood-stage malaria vaccine candidate. Immunological mechanisms responsible for 
eliminating malaria parasites remain unclear, but antibodies to the carboxyl-terminal 19-kDa 
segment of the MSP1-19 have been implicated. This study aimed to determine the prevalence 
of anti-MSP-119 antibodies in pregnant women.  
In a prospective, case-control study, antibody levels in pregnant and non-pregnant women 
were compared using bulk ELISA technique. Results showed that the antibodies levels to 
MSP-119 in pregnant women were lower compared to non-pregnant. Furthermore, 
multigravidae have higher anti- MSP1-19 antibodies levels compared to primigravidae. On the 
other hand, increasing prevalence of anti-MSP-119 antibodies with the increase in age in 
pregnant women could be detected. 
In conclusion: low anti- MSP1-19  could be a possible explanation for the increased pregnancy 
-associated malaria in pregnant women especially primigravidae. 
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Introduction 
 
 
Malaria is one of the major health problems in Sudan and pregnant women are at greater risk 
for developing malaria. Merozoite surface proteins-119 of P.falciparum are important malaria 
vaccine candidates, and collection of information about humoral responses to this antigen 
will help in choosing candidate vaccines. The studies of prevalence of anti-MSP119 
antibodies in pregnant women will also help in setting future control programs, especially 
vaccination. 
The objective of the study is to determine the prevalence of anti-P.falciparum merozoite 
surface protein (PfMSP-119) antibodies in pregnant women using bulk ELISA technique. 
 
 
 
 
 
 
CHAPTER ONE 
      
LITERATURE REVIEW 
1.1 The Malaria problem:  
Malaria infection is endemic across the tropics and subtropical regions; it affects people in 
more than 90 countries, causing 300–500 million infections/year and is estimated to lead to 
approximately 1 million deaths each year (Breman, 2001; Murphy & Breman, 2001). Most 
infections and most severe morbidity and mortality are caused by Plasmodium falciparum. 
The other three human malaria parasites (P.vivax, P.malariae and P.ovale) contribute to fewer 
infections and to moderate disease and relatively few deaths (Mendis, et al., 2001). Most 
P.falciparum infections and consequences are in sub-Saharan Africa, but Asia, Southeast 
Asia and the Americas are also sites of transmission for this parasite. Although a few reports 
of adverse consequences of P.vivax in pregnancy exist (Nosten, et a., 1999). P.falciparum is 
the only human malaria parasite that is more common in pregnant than in non-pregnant 
women and is the only human parasite that has substantial adverse effects on pregnancy, and 
pregnancy outcome (Brabin, 1991; Steketee, et al., 2001). 
 
 
1.2 The Burden of Malaria in Sudan: 
 
Malaria is endemic throughout the Sudan. Endemecity varies from hypo-endemic in the 
North to hyper-to-holo endemic in the South. The disease is caused in > 90% of cases by 
Plasmodium falciparum. Annually, malaria is estimated to lead to 7.5 million cases and 
35,000 deaths. (WHO/EMRO, 2001). 
Also according to the annual statistical report of the Federal Ministry of Health 17.4 - 44.8% 
of all out-patient clinic visits are due to malaria. Between 9.6 – 36.3% of all hospital 
admissions are a consequence of malaria and malaria is a leading cause of reported deaths, 
contributing to 10–15% of total deaths that occur at hospital level (FMOH, 2003). 
 
1.3 Malaria in pregnancy:  
Malaria infection during pregnancy is a major public health problem in tropical and 
subtropical regions throughout the world. In most endemic areas of the world, pregnant 
women are the main adult risk group for malaria. Malaria during pregnancy has been most 
widely evaluated in Africa south of the Sahara where ninety percent (90%) of the global 
malaria burden occurs. The burden of malaria infection during pregnancy is caused chiefly by 
Plasmodium falciparum, the most common malaria species in Africa. Every year at least 30 
million pregnancies occur among women, in malarious areas of Africa, most of who reside in 
area of relatively stable malaria transmission (WHO/EMRO, 2001). In Africa perinatal 
mortality due to malaria is at about 1500/day. In areas where malaria is endemic, 20-40% of 
all babies born may have a low birth weight (Kakkilaya, 2004). 
In the Sudan each year more than 1.2 million women become pregnant, of those 750,000 are 
in areas with high malaria transmission: intense perennial, high seasonal transmission or in 
areas of irrigation (FMOH; RBM, 2004). Malaria contributed considerably to maternal 
morbidity. It accounted for 37.2% of all maternal deaths in Sudan at hospital level     
(Dafalla, et al., 2003). Also it was found to be a cause of 18.1% of low birth weight       
(Taha, et al., 1995).  
 
 
 
1.4 The symptoms and complications of malaria during pregnancy:  
The symptoms and complication of malaria during pregnancy differ with the intensity of 
malaria transmission and thus with the level of immunity the pregnant women has acquired. 
According to the Malaria and Pregnancy Network (2000) malaria causes up to fifteen percent 
of maternal anaemia and about thirty five percent of preventable low birth weight. Low birth 
weight is a leading cause of neonatal mortality.  
The clinical features of Plasmodium falciparum malaria in pregnancy depend to a large 
extent on the immune status of the women. In pregnant women with little or no pre-existing 
immunity, such as women from non-endemic areas or travelers to malarious area, infection is 
associated with high risks of severe disease with maternal and perinatal mortality. These 
women are at particular risk of cerebral malaria, hypoglycaemia, pulmonary oedema and 
severe haemolytic anaemia. Fetal and perinatal loss has been documented to be as high as 60-
70% in non-immune women with malaria (Shulman and Dorman, 2003).  
Pregnancy-associated malaria is characterized by the sequestration of P. falciparum-infected 
erythrocytes in placental intervillous spaces. Placental parasites appear to express a specific 
phenotype defined by the adherence of P.falciparum- infected erythrocytes to the 
glycosaminoglycans Chondroitin sulfate A (CSA) and hyaluronic acid, expressed by the 
syncytiotrophoblast (Fried and Duffy, 1996; Beeson, et al., 2000). Parasite adhesion to CSA 
is mediated by P.falciparum-variant surface antigens (VSAs) expressed on the surface of 
infected erythrocytes (Buffet, et al., 1999; Reeder, et al., 1999) Placental parasites bind to 
CSA and not to other VSAs ligands, such as CD36 and ICAM-1, whereas the opposite is true 
for most parasite isolates from non-pregnant individuals (Fried and Duffy, 1996; Beeson, et 
al., 2000; Maubert , et al., 2000).  
 1.5 Malaria Antigens For MalariaVaccine Development: 
The complex life cycle of the malaria parasite has complicated vaccine development efforts. 
Each parasite stage has different antigens (table 1) that lead to protective immunity and 
immune responses effective against one stage (for example, sporozoites), but that generally 
have been ineffective against other parasite stages (such as the asexual and sexual stages). 
This has resulted in a rich diversity of approaches to malaria vaccine development and to 
multiple current vaccine candidates (Hoffman, 1996). These antigens are classified as the 
follows: 
 
1.5.1 PRE-ERYTHROCYTIC PHASE ANTIGENS: 
 
1.5.1.1 Circumsporozoite Protein (CS or CSP)  
The circumsporozoite protein is the main sporozoite coat protein. It has a central area 
consisting of repeat sequences that are highly immunogenic and present in the differing 
malaria species. Studies reveal that the central repeat region can elicit a B-cell immune 
response, producing antibodies that block sporozoites in culture. Induces CD8+ and CD4+ 
CTL response in mice (Zevering, et al., 1998). 
 
1.5.1.2 Sporozoite Surface Protein 2 (SSP2) 
SSP2 is a protein found on the surface of sporozoites from the murine malaria parasite P. 
yoelii.  The equivalent protein found in P. falciparum is known as thrombospondin-related 
anonymous protein (TRAP). It possesses a sequence homologous to the conserved region II 
of the CS protein. Antibody raised to recombinant P. falciparum TRAP was demonstrated to 
inhibit sporozoite invasion of hepatoma cells in vitro (Nardin and Nussenzweig, 1999). 
  
1.5.1.3 Liver Stage-Specific Antigen (LSA-1)  
LSA-1 is first expressed in infected liver cells. It has a 17 amino acid repeat and is 
immunogenic it causes CTL response in Africans that gives protection to severe malaria 
(Hollingdale, 1998). 
 
1.5.2 ERYTHROCYTIC PHASE ANTIGENS: (Table A) 
1.5.2.1 Merozoite Surface Protein 1 (MSP-1/MSA-1) (Fig. 2) 
 Several merozoite surface proteins have been described. The best characterized is merozoite 
surface protein-1 (MSP-1). It is the major surface antigen of merozoites and is the best-
studied protein (Reeder, 2001). PfMSP-1 is synthesized as a polypeptide of ~ 195 KD, 
which is subjected to several proteolytic cleavages during maturation of the merozoite 
(Stafford, et al., 1994). This proteolytic processing is coincident with merozoite maturation 
and invasion (Cooper, 1993). During the first phase, it is cleaved to yield four peptide 
fragments, of which the 42 kDa C-terminal fragment (MSP1-42) remains fixed to the 
merozoite membrane. During the second phase, occurring at the moment of erythrocyte 
invasion, MSP1-42 itself is cleaved to yield a polypeptide of molecular weight 19 kDa 
(MSP1-19). The latter cleavage is essential for erythrocyte invasion (Pizarro, et al., 2003). 
The highly conserved 19-kDa C-terminal processing fragment (MSP-119) contains epitopes 
targeted by antibodies that inhibit erythrocytic invasion. This 19-kDa antigenic domain is a 
potential malaria vaccine candidate (Qari, et al., 1998). 
 
1.5.2.2 Merozoite Surface Protein 2 (MSP-2)  
MSP-2 is a glycoprotein with a molecular size of 45-kD. It has a central repeat region that has 
significant variation among isolates while the N- and C- terminal regions are well conserved. 
The antibody response is directed almost completely towards variant regions of MSP-2. The 
conserved regions are rarely recognized (Taylor, et al., 1998). 
 
1.5.2.3 Apical membrane antigen I (AMA-1)  
Apical Merozoite Antigen 1 is a membrane protein produced in the apical organelles of the 
merozoite. During invasion of erythrocytes, AMA1 redistributes over the entire surface of the 
parasite, and like MSP1, is proteolytically cleaved. The sequence of AMA-1 is relatively 
conserved with greater than 50% amino acid conservation among the different Plasmodium 
species, is a leading malaria vaccine candidate. Known to stimulate humoral response in 
patients with chronic malaria. It also seems to stimulate T-cell response in vitro (Amante, 
1997). 
1.5.2. 4 Erythrocytic-Binding Antigen (EBA-175): 
EBA-175 is a transmembrane protein characterized by two conserved cysteine-rich domains 
and is expressed on the surface of merozoites. It thought to be involved in attaching 
merozoites to erythrocyte receptors via sialic acid during invasion. Immunizing rabbits with 
this protein can give blocking effect to merozoite invasion (Clough, 1996). 
1.5.2.5 Ring-Infected Erythrocytic Surface Antigen (RESA): 
RESA is expressed on erythrocytes infected with ring stage parasites. Causes humoral 
immune response. In vitro RESA inhibits IL-2 levels. Evidence of intrauterine protection 
passed to fetuses via this Ag (Chaba, et al.1998). 
 
1.5.2.6 Other Antigens: 
Other antigens include serine repeat antigen (SERA) or serine- rich protein (SERP), 
glycophorin binding protein (GBP-130), histidine rich protein 2 (HRP-2), rhoptry-associated 
proteins (RAP-1 and RAP-2), Pfs230 and Pfs40  (Staalso, et al., 1998). 
 
1.5.3 ANTI-DISEASE ANTIGENS: 
1.5.3.1 Erythrocyte Membrane Proteins 1 (PfEMP1) (Fig.1):  
After invading the erythrocyte, Plasmodium falciparum expresses the virulence factor 
PfEMP1, which is transported to the surface of the red blood cell (Pizarro, et al., 2003). 
PfEMP1 is a member of the var gene family. The 40-50 var genes exhibit a high degree of 
variability, but have a similar overall structure (Figure 1). PfEMP1 has a large extracellular 
N-terminal domain, a transmembrane region and a C-terminal intracellular domain. The C-
terminal region is conserved between members of the var family and is believed to anchor 
PfEMP1 to the erythrocyte submembrane cytoskeleton. (Smith, el al., 2001). PfEMP1 
probably functions as a ligand that enables the infected-RBC to cytoadhere to various host 
cell receptors, including the scavenger receptor CD36, an 88-kDa intergral membrane protein 
found on monocytes, platelets and endothelial cells. Another receptor is intracellular adhesion 
molecule-1 (ICAM1). ICAM1 is a member of the immunoglobulin superfamily and functions 
in cell-cell adhesion. Chondroitin sulfate A (CSA) has been implicated in the cytoadherence 
within the placenta and may contribute to the adverse affects of P. falciparum during 
pregnancy (Beeson and Brown, 2002). An other receptors are platelet endothelial cell 
adhesion molecule-1 (PECAM-1), thrombospondin (TSP) (Shulman et al., 2003). These 
adhesions assist the parasite in escaping splenic clearance and promote sequestration of 
parasites in vital organs such as brain and placenta. (Beeson and Brown, 2002).    
 PfEMP1 is an adhesin molecule, which confers on the infected erythrocyte the capacity to 
auto-agglutinate, to adhere to uninfected red blood cells or to be sequestered on vascular 
endothelial cells in diverse tissues. Agglutination and sequestration of infected erythrocytes 
are correlated with many of the pathogenic effects of malaria (Pizarro, et al., 2003) 
Antibodies to variable regions of these proteins, measured by agglutination, correlates with 
clinical protection against falciparum malaria (Staalso, et al., 1998). 
 
1.5.3.2 Sequestrin  
Sequestrin is a 270-kDa surface knob protein that is expressed on the surface of infected 
erythrocytes and it is a ligand for CD36. This surface protein is also a good vaccine candidate 
except that it shows a high rate of antigenic variation (Sharma, 1997). 
 
1.5.3.3 Others  
Two glycoproteins that are released upon schizonts rupture are currently being studied. They 
are shown to induce release of tumor necrosis factor (TNF-β), which may be a factor in the 
onset of malaria related illness (Tolle, et al., 1993). 
 
1.5.4 Transmission Phase Antigens:  
1.5.4.1 Pfs25  
Pfs25 is found on the surface of P. facliparum zygotes and ookinetes. Inside the mosquito, 
monoclonal antibodies to the Pfs25 antigen can block development of the sexual stages, thus 
inhibiting the production of sporozoites. Pfs25 seems to be the most promising sexual blood 
stage antigen that may someday be used in a vaccine (Staalso, et al., 1998).  
 
1.6 Immunity to malaria and antigenic variability of P. falciparum: 
P.falciparum parasites show a remarkably high degree of polymorphism at the various stages 
of their life cycle, which has important implications for the efficacy of parasite-neutralizing 
immune responses (Lockyer, et al., 1989; Bull, et al., 1998; Miller, et al., 1993; Fenton, et al., 
1991; Konate, et al., 1999). Antigenic diversity in field populations of P.falciparum parasites 
may delay acquisition of protective immunity to malaria, the development of which may thus 
require repeated exposure to many different antigenic types or strains circulating in a given 
locality. The antigenic diversity reflects polymorphisms in allelic gene products while 
polymorphisms in many antigens are caused by variations in the sequence of the short tandem 
repeats, which is a characteristic of many malaria antigens and which frequently constitute 
immunodominant regions. MSP1 and MSP2 genes are the best-studied with regard to allelic 
polymorphisms (Snounou et al., 1999). 
Antigenic variation is a process by which a clonal parasite population can switch its antigenic 
phenotype (Gardner, et al., 2002). In P.falciparum the variant antigens are expressed at the 
surface of infected erythrocytes and the expression of these antigens can be modulated in a 
given parasite population either by immune pressure or transfer from intact to splenectomized 
animals. Antigenic variation is usually considered as a mechanism that allows parasite survival 
in an immune-competent host. However, antigenic variation of PfEMP-1 can also occur in vitro 
in the absence of immune pressure (Biggs, et al., 1991; Roberts, et al., 1992). 
Although resistance to infection with malaria parasites and to the disease itself increases with 
age in individuals living in endemic areas, it can take more than a decade to reach substantial 
protection, and never reaches completion. The age at which maximal protection is reached 
also correlates inversely with the intensity of parasite transmission (mosquito-human); 
therefore, these observations could support the hypothesis that the malaria antigens that 
induce protective immune responses might be poorly immunogenic (weak inducers of 
immunity). Alternatively, these antigens might be very polymorphic (varying between 
different strains of P.falciparum - antigenic diversity) or variable (changing with time within 
individual strains-antigenic variation), therefore requiring the accumulation of immunological 
memory (acquired immunity) to a large number of different antigenic epitopes before 
substantial protection is achieved. Indeed, a number of recent studies point to the latter 
possibility (Taylor and Robinson, 1998). 
 
1.7 Immune responses to maternal malaria: 
The immune response to malaria is not well understood.  There has been some recent 
research into the unique immune response offered by pregnant women against malaria.  
One popular model, emerging in the last decade, to explain the unique susceptibility of 
pregnant women to malaria is that of pregnancy-associated immunosuppression.  According 
to this model, pregnancy induces a state of general immunosuppression in the body sustained 
by elevated levels of serum cortisol.  This immunosuppression prevents fetal rejection and 
thus, renders pregnant women susceptible to infection.  However, this theory does not explain 
the diminished susceptibility to malaria experienced by multigravid women.  (Meeusen, et 
al., 2001) showed that Pregnancy is characterised by a transient depression of cell-mediated 
immunity of the woman that allows foetal allograft retention, but also interferes with 
resistance of the mother to various infectious diseases. Cellular immune responses to P. 
falciparum antigens are depressed in pregnant women compared to non-pregnant controls 
(Fievet, et al., 1995; Riley, et al., 1998). This pregnancy-induced immunosuppression may 
persist several months after delivery, but generally restoration of immune responses to P. 
falciparum antigens is being observed within six months after delivery (Fievet, et al., 1997; 
Diagne, et al., 2000). 
Studies in pregnant women have reported that anti-P. falciparum antibodies to three asexual-
stage antigens appear to be associated with protective immunity. Two studies have shown 
that pregnant women who lack antibodies to the ring-infected stage antigen (RESA) are more 
susceptible to P.falciparum infection (Astagneau, et al., 1994; Mvondo, et al., 1992). 
However, two other studies have not found this association (Deloron, et al., 1989; Fievet, et 
al., 1995). The ability of anti-RESA antibodies to reduce placental parasitemia has not been 
investigated. In 1996, Fried and Duffy reported that parasites sequestered in the placenta 
express a ligand that binds specifically to chondroitin sulfate A (CSA) (Fried and Duffy, 
1996). The ligand, CSA-L, is thought to be a variant of P. falciparum erythrocyte membrane 
protein 1 (Fried and Duffy, 1996; Fried, et al., 1998). Since antibodies inhibit the binding of 
IRBC to CSA in vitro (Alkhalil, et al., 2000; Fried et al., 1998; Maubert, et al., 1999; O'Neil-
Dunne, et al., 2001; Ricke, et al., 2000), they are likely to be protective in vivo.  Branch, et 
al., in 2000, reported that placental parasite densities were significantly lower in Kenyan 
mothers who had immunoglobulin G (IgG) antibodies to the carboxyl-terminal 19-kDa 
segment of the merozoite surface protein 1 (MSP-119) than mothers who did not. 
Recently, it has been shown that almost all pregnant women lack anti-CSA-L antibodies at 
conception (O'Neil-Dunne, et al., 2001). In a study from Burundi, it was shown that 
multigravid women begin producing significant anti-adhesion antibodies during the fourth 
month of gestation, whereas primigravidae do not begin producing these antibodies until 
around 6 months (O'Neil-Dunne, et al., 2001). 
A longitudinal study in Africa, demonstrated that pregnant women were more susceptible to 
malaria during first pregnancies than second pregnancies (Fievet, et al., 1997). Bull and 
colleagues recently reported that disease protection is dependent on a variant-specific 
immune protection directed against a variety of members of the PfEMP1 family (Bull, et al., 
1998). Antibodies to MSP-119 can block merozoite invasion, either by inhibiting the binding 
of merozoites to erythrocytes by blocking processing of MSP-1 or by other mechanisms 
(Blackman, et al., 1994; Guevara, et al., 1997; Holder, et al., 1999). 
 
 1.8 Malaria in pregnancy and the role of chondroitin sulfate A: 
Women living in endemic areas who are resistant to malaria before their pregnancy tend to 
lose this protection when they become pregnant (Brabin, 1983). This observation has often 
been interpreted as a consequence of the immunosuppression that is necessary to protect the 
fetus from being rejected by the mother's immune system (Weinberg, 1984). However, in 
malaria-endemic areas this increased susceptibility to malaria (which can cause severe 
disease in the mother as well as abortion, stillbirth and low birth weight of the offspring) is 
disproportionately higher in women undergoing a first pregnancy (primigravidae) 
(McGregor, 1987). These women have not been exposed to and have no immunity to such 
parasites before becoming pregnant. The first pregnancy enables them to develop specific 
immunity, which protects them during subsequent pregnancies. This hypothesis is supported 
by the fact that multigravid pregnant women in endemic areas have antibodies to placental 
parasites acquired during previous malaria-infected pregnancies, (Maubert, et al., 1999). 
These antibodies inhibit the cytoadherence of placental parasites to human 
syncyliotrophoblast (Ricke, et al., 2000).      
The parasitized RBCs found in the placentas of women experiencing their first pregnancy 
show a remarkable preference to bind to chondroitin sulfate A (CSA), which is a ligand that 
is present on the placental syncytiotrophoblast but is not readily accessible on cells elsewhere 
in the body (Fried and Duffy, 1996; Maubert, et al., 1997). The molecule in the parasite that 
mediates binding to CSA appears to be a particular variant of PfEMP1 (Reeder, et al., 1999). 
The high frequency of parasites found in the placenta that bind CSA can explain the 
susceptibility of primigravidae to clinical malaria and points to the importance to protection 
of immunity that is specific for parasite variants (Ricke, et al., 2000). These adhesion 
specificities are eliminated from a non-pregnant individual, owing to a lack of suitable 
adhesion receptors on the host cells, and presumably before they have induced appreciable 
levels of antibodies to the CSA-specific PfEMP1 variant. In contrast, because CSA becomes 
available in the developing placentas of primigravidae, parasites that are able to bind CSA 
and are present in the blood can suddenly multiply unhindered. With successive pregnancies, 
the levels of the antibodies that are directed against PfEMP1 variant molecules that can bind 
CSA increase, and are therefore able to limit the multiplication of CSA-binding parasites 
(Ricke, et al., 2000). Protection against pregnancy-associated malaria can be gradually 
acquired in this way. It has recently been discovered that most P.falciparum isolates from 
infected placentas can also bind to hyaluronic acid, a second receptor for parasite adhesion 
that is present on the placental lining (Beeson, et al., 2000) these findings are changing our 
understanding of the mediation of placental parasite accumulation, there is still much to 
discover about the reasons for the increased susceptibility of pregnant women to malaria and 
the pathogenesis of placental malaria (Maubert, et al., 1997; Beeson, et al., 2000). 
 
1.9 Vaccination against malaria: 
Despite long and intensive research efforts, no vaccine against malaria in humans is yet 
available; this is in spite of recent advances particularly with sporozoite vaccines (Stoute, et 
al., 1997; Seder and Hill, 2000). Several different approaches, both in terms of antigens and 
technologies, are being taken by various research groups (Taylor and Robinson, 2000), but 
they are all focused on relatively conserved parasite antigens. If variant-specific responses are 
as important to the natural acquisition of protective immunity as some of the data might 
suggest, it follows that a strategy of artificial immunization based on responses to conserved 
parasite antigens must induce immune responses that are very different to those induced by 
natural exposure to P. falciparum in endemic areas. One hope lies with PfEMP1, antibodies 
to which show significant correlation with development of clinical immunity (Bull, et al., 
1998; Bull, et al., 2000). Unfortunately, the variant nature of PfEMP1 remains a major 
obstacle for vaccine design, as the immune response to it is highly variant-specific. However, 
the recent demonstration that monoclonal antibodies recognize cross-reactive epitopes of the 
cysteine-rich interdomain region 1 (CIDR1) of PfEMP1. These epitopes are functionally 
conserved for binding to the CD36 ligand expressed by host epithelial cells (Fig.1), provides 
credence for development of effective vaccines against this variant antigen. Whether this will 
be possible remains to be seen (Gamain, et al., 2001). 
Although a general malaria vaccine appears to be a distant possibility, there is much hope for 
a vaccine against placental malaria. As aforementioned, Fried and Duffy have proven that 
multigravid women are able to mount an effective antibody response against parasite 
sequestration on the placental surface. Presently, two possibilities have been explored with 
respect to parasite adhesion to the chondroitin sulfate A receptor. First, the administration of 
excessive soluble CSA to pregnant women has proven to drastically reduce parasite adhesion; 
however, in excess levels, this soluble protein is severely nephrotoxic. Second, studies have 
demonstrated that the administration of chondroitinase AC can effectively reduce parasite 
adhesion by 95%. This preliminary data is being further tested in combination with 
therapeutic use of monoclonal antibodies to CSA ( Fried and Duffy, 1998).  
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
Materials and Methods 
 
2.1 The Study Area: 
This study was conducted at Omdurman Maternity Hospital, which is a central referral 
maternity hospital that was established in 1957. Since then the hospital has continued to 
provide obstetric and paediatric care to an increasing population, which has reached 2.5 
million in its catchments area. The hospital has 134 beds, 2 labour wards, 3 surgical theatres, 
a blood bank, and a laboratory. In 2003 deliveries at the hospital reached 17,288.  Attached to 
the hospital is the First School of Midwifery in Sudan. 
 Malaria transmission is seasonal malaria related to rain fall, P. falciparum is the predominant 
species, and accounts for 95% of all malaria cases in the hospital catchments area.  Anopheles 
arabiensis is the main vector (FMOH; RBM, 2004). 
 
2.2 The study design: 
A longitudinal, prospective study was carried out at Omdurman Maternity Hospital, and 
Institute of Endemic Diseases, from December 2003 to October 2004. 
 
2.2.1 Study population:  
 The study population consisted of 100 women, of whom 67 were pregnant women (first, 
second, and third trimester) and 33 were non pregnant. Each woman received a unique index 
number. Following informed consent, all recruited women were clinically examined and 
screened for malaria at the beginning of the study.  All women were interviewed in a special 
questionnaire form that contained demographic data, number of pregnancies, gestational age, 
and past history of malaria attacks.  
2.2.2 Blood sampling: 
Venous blood samples were collected [2-5ml] in vacutainers from all women, for 
parasitological (smears), haematological and serological (ELISA) investigations. . 
 
2.2.3 The health team: 
The health (investigating) team consisted of: a medical doctor, microscopist, and two 
assistants. 
 
2.3 The laboratory work: 
The laboratory work was carried out at the medical laboratory in Omdurman and the Institute 
of Endemic Diseases, University of Khartoum. 
 
2.3.1 Preparations of thick and thin films: 
Air-dried thick and thin blood films were stained with Giemsa (10%) for ten minutes and 
then examined for parasitaemia by trained technicians.          
 
2.3.2 Serum preparations: 
Serum was collected in plain tubes after the clotted whole blood was centrifuged for fifteen 
minutes at 1000 rpm and stored frozen at -20 °C for later anti-body estimation.  
Sera of non-exposed donors were used as negative controls. While sera from individuals 
having high anti-body level (or showed a high clear positive anti-bodies response to the 
different fragments of the merozoite surface proteins) were used as positive controls. 
 2.3.3 Enzyme-linked immunosorbent assays (ELISA) for the detection of human antibodies 
using recombinant MSP-119: 
ELISA technique used is known of its ability to recognize the recombinant MSP119 as 
described by Cavanagh (2001).  
Recombinant antigen fragments (PfMSP119) were used in the assay. The GST (Glutathion-s-
transferase) control protein was included on all plates in order that the Optical Density (OD) 
reading specific for PfMSP1, could be calculated.  Sera were examined in duplicates. This 
involved subtracting the average OD of antibodies against GST from the average OD of the 
antibodies directed against duplicate wells coated with the recombinant antigen, thus 
obtaining the specific anti-MSP119 recombinant antigen OD.  
Ninety six wells microtitre plates were coated with 50 ng/well of recombinant antigens 
(MSP-119) in 100 µl of coating buffer (15mM Na2CO3, 35 mM NaHCO3, pH 9.3), and 
incubated in the dark for three days at 4oC. The wells were emptied, and washed three times 
with the washing buffer (0.05% Tween 20 in PBS). Unoccupied protein binding sites were 
blocked with 200 µl/well blocking buffer (1% [w/v] skimmed milk powder in washing 
buffer) for 5 hours at room temperature and washed again three times by washing buffer.  
Hundred µl per well of the human sera (diluted 1:500 in the blocking buffer) were added to 
duplicate antigen-coated wells and incubated overnight at 4oC. After three washes with 
washing buffer, the wells were incubated for 3 hours with 100 µl/well of the horseradish 
peroxidase-congugated rabbit anti-human IgG  (1:5000 in the blocking buffer), and washed 
three times. Then incubating for up to 15 minutes at room temperature with 100 µl/well of 
substrate (0.1 mg ml-1 O-phenylene-diamine (OPD) [Sigma] and 0.12% H2O2) in 
development buffer (24.5 mM citric acid monohydrate and 52 mM Na2HPO4, pH 5.0).   
Finally the reaction was stopped by addition of 20 µl/well of sulphuric acid (2M H2SO4). 
Optical densities (OD) were measured at 490 nm using the plate reader. The corrected OD 
value for each sera sample was involved subtracting the average OD of antibodies against 
GST from the average OD of the antibodies directed against duplicate wells coated with the 
recombinant MSP-119 antigen. 
 
2.4 Control sera: 
Negative control plasma samples were collected from healthy donors who had not been 
exposed to malaria. A positive control from a malaria endemic area was used for comparison 
with the cohort of samples tested. The cut-off point was calculated as: 
Cut-off point = Mean OD of the negative controls readings + 3 SDs. 
The cut off point was calculated as 0.13 OD 
All the titration which were above the cut-off point were considered as positive plasma, and 
all those under the cut-of point were considered as negative sera.                                                
 
 
 
 
                                                           CHAPTER THREE 
 RESULTS 
 
3.1 Population and the history of malaria: - 
The total number of the population of the study was hundred. Pregnant women were 67% of 
the study population, (aged between 19-40years), while non-pregnant constituted 33% (ages 
19-45 years). Forty four % (30/67) were primigravidae, and 55.2% (37/67) were 
multigravidae. 
Past history of malaria was more frequent among non-pregnant women (table 1), where it 
was reported more frequently in women over 30 years of age, while in pregnant women 
previous malaria attacks were more common among women aged between 20-30 years   
(table 2). Also was reported more frequent among multigravid women (table 6). 
Parasitologically, 5/67 (7.5%) pregnant women tested positive, while only 1/33 from non-
pregnant women tested positive (table 1). 
 
3.2 Prevalence of anti-MSP-119 antibodies: - 
The hundred women who participated in this study were screened to determine the 
prevalence of anti-MSP-1 antibodies. The number and percentages of prevalence of MSP-119 
antibody are shown in (table-1). 
Antibody levels were categorized into two groups, those with levels <0.13 (Negative) and 
those with levels >0.13 (Positive). Although malaria was more prevalent in pregnant women, 
the percentage of women with positive levels for anti-MSP1-19 antibody were more in non-
pregnant women (table 1). 
Pregnant women ≤ 30 year had higher levels of anti-MSP119, while in non-pregnant women, 
higher levels of anti-MSP-119 antibodies were found > 30years of age (table 3). Multigravid 
women had higher levels of anti-MSP-119 antibodies (table 5). 
  
 
Table (1): History of malaria attacks & anti-MSP1-19 bodies levels in the study population: 
 
 
 
 
 
 
 
 
       
 
Previous history of malaria 
 
Parasitology for  malaria 
 
Level of anti-MSP-119 
 
 
      
 
     
 
 
 
 
 Numbers 
 
      
     Positive 
 
                        
Negative 
 
 
 
    
  Positive 
 
    
  Negative 
 
      
  Positive 
 
    
  Negative 
 
 
Pregnant 
 
 
67 
 
49 
(73.1%) 
 
18 
(26.9%) 
 
 
5 
(7.5%) 
 
62 
(92.5%) 
 
50 
(75.8%) 
 
16 
(24.2%) 
 
 
Non-pregnant 
 
 
33 
 
26 
(78.8%) 
 
7 
(21.2%) 
 
 
 
1 
(3.0%) 
 
32 
(97.0%) 
 
28 
(84.8%) 
 
5 
(15.2) 
 
 
 
 
 
Table (2): Distribution of previous history of malaria according to age-groups: 
 
 
                      +ve:  positive 
                       -ve:  Negative 
 
 
Pregnant 
 
Non-pregnant  
Age Group 
Total number +ve -ve TN +ve -ve 
 
<21 
 
12(17.9%) 
 
8(11.9%) 
 
4(6.0%) 
 
1(3.0%) 
 
1(3.0%) 
 
_ 
 
21-30 
 
35(52.2%) 
 
25(37.3%) 
 
10(14.9%) 
 
11(33.3%) 
 
8(24.2%) 
 
3(9.1%) 
 
31-40 
 
20(29.9%) 
 
16(23.9%) 
 
4(6.0%) 
 
18(54.5%) 
 
15(45.5%) 
 
3(9.1%) 
>40  
_ 
 
_ 
 
_ 
 
3(9.1%) 
 
2(6.1%) 
 
1(3.0%) 
 
Total 
 
67(100%) 
 
49(73.1%) 
 
18(26.9%) 
 
33(100%) 
 
26(78.8%) 
 
7(21.2%) 
  
Table (3): Anti-MSP-119 antibody levels in different age-groups in the study population: 
 
  
 
Age-groups 
 
 
                    
 
 
 
 
                   
 
< 21 
 
21-30 
 
31-40 
 
> 40 
 
 
Number 
 
Positive 
 
Negative
 
Number
 
Positive
 
Negative
 
Number 
 
Positive 
 
Negative
 
Number
 
Positive
 
Negative
 
 
Pregnant 
 
   12 
(18.2%) 
 
   10 
(15.2%) 
 
 
    2 
(3.0%) 
 
 
 
   34 
(51.5%) 
 
    22 
(33.3%) 
 
 
     12 
(18.2%) 
 
 
   20 
(30.3%) 
 
    18 
(27.3%) 
 
 
    2 
(3.0%) 
 
     
     – 
 
 
     − 
 
 
    – 
 
 
Non pregnant 
 
   1 
(3.0%) 
 
   1 
(3.0%) 
 
 
      – 
 
    11 
(33.3%) 
 
    8 
(24.2%) 
 
    3 
(9.1%) 
 
   18 
(54.5%) 
 
    17 
(51.5%) 
 
    1 
(3.0%) 
 
    3 
(9.1%) 
 
    2 
(6.1%) 
 
    1 
(3.0%) 
 
 
 
 
 
                    Table (4): Distribution of parity in different age-groups in the study population: 
 
 
 
        Age-group 
 
Primigravidae 
 
Multigravidae 
 
Total 
 
< 21 
 
8(11.9%) 
 
4(06.0%) 
 
12(17.9%) 
 
21-30 
 
20(29.9%) 
 
15(22.4%) 
 
35(52.2%) 
 
31-40 
 
2(03.0%) 
 
18(26.9%) 
 
20(29.9%) 
 
Total 
 
30(44.8%) 
 
37(55.2%) 
 
67(100.0%) 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table (5): The distribution of anti-MSP1-19 antibody levels according to parity 
 
 
 
 
 
 
 
 
 
 
 
                           Positive= above a designated cut off level. 
               Negative= below a designated cut off level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number 
 
Negative 
 
Positive 
 
Primigravidae 
 
30 (44.8%) 
 
12(17.9%) 
 
18(26.9%) 
 
Multigravidae 
 
37 (55.2%) 
 
4(06.0%) 
 
32(47.8%) 
 
 
 
 
 
 
 
Table (6): Comparison of previous history of malaria and antibody levels according to parity 
 
 
                           
 
Previous history of malaria 
 
 
Antibody levels 
 
 
 
 
 
Number 
 
Positive 
 
Negative 
 
Positive 
 
Negative 
 
 
Preimigravidae 
 
 
30(44.8%) 
 
 
23(76.7%) 
 
 
7(23.3%) 
 
 
18(26.9%) 
 
 
12(17.9%) 
 
 
Multigravidae 
 
 
37(55.2%) 
 
 
26(70.3%) 
 
 
11(29.7%) 
 
 
32(47.8%) 
 
 
4(06.0%) 
 
 
 
 
 
CHAPTER FOUR  
 
Discussion 
 
It was clear from this study that anti-MSP-119 antibodies were low in pregnant women 
compared to non-pregnant controls. This is generally in line with the immunosuppressive 
theory of pregnancy (McGregor, 1987). The relatively high levels in multigravid women 
was probably due to more previous exposures of these women compared to primigravidae 
as those also tended to be younger in the study group. This agrees with Oralee et al., 
(2000), who suggested that the MSP1-19 antibody response develops with age, not with 
multiple experiences with parasitemia. These antibodies are important in the development 
of cumulative protective immunity to malaria. This finding also agree with Meeusen et 
al., (2001) who discussed immune response to maternal malaria and reported that, the 
sustained immune-suppression during pregnancy prevents fetal rejection, but does not 
explain the diminished susceptibility to malaria experienced by multigravid women. 
However, earlier findings reported that, multigravid pregnant women in endemic areas 
have antibodies to placental parasites acquired during previous malaria-infected 
pregnancies (Maubert, et al., 1999). These antibodies were claimed to inhibit the 
cytoadherence of placental parasites to human syncyliotrophoblast. (Ricke, et al., 2000). 
It is not clearly understood whether the antigen molecules that induced antibodies 
production play a role in long-term immune responses and protection against malaria. P. 
falciprum.   
Antibodies estimated in the present work, were known to be produced against the MSP1-
19 antigenic domain which is a potential vaccine candidate. Binding of these antibodies to 
their epitope inhibits erythrocytic invasion by the merozoites (Qari et al., 1998). 
 II
 In this study, the prevalence of the positive anti- MSP1-19 among the study group was 
84.8% in non-pregnant women compared to only 75.8% in pregnant ones (Table 1). This 
finding seems to agree with a previously reported observation by Brabin, (1983) who 
showed that women living in endemic areas were resistant to malaria before their 
pregnancy and tended to lose this protection when they become pregnant.  
The immune suppressive theory of pregnancy was further supported by Fievet et al., 
(1995) and Riley, et al., (1998) who reported that cellular immune responses to P. 
falciparum antigens were depressed in pregnant women in comparison with non-pregnant 
controls This observation has also often been interpreted as a consequence of the 
immunosuppression that is necessary to protect the fetus from being rejected by the 
mother's immune system (Weinberg, 1984).  
The prevalence of positive anti- MSP1-19 in multigravidae women in the present study 
was two times the positive cases in primigravidae group (Table 5). This finding may 
corroborated previous findings reported by Fried, et al., (1998) and Maubert, et at., 
(1999) who claimed that reduced incidence of malaria infections in multigravid women 
could be due to antibodies directed against pregnancy-associated parasites acquired 
during the first infected pregnancy that inhibit the cytoadherence of placental parasites to 
the human syncytiotrophoblast. Although some studies reported the absence of antibodies 
in primigravidae, other studies have shown that primigravidae do produce anti-adhesion 
antibodies. Most studies have reported increased levels of antibodies with increasing 
gravidities (Gysin,et al.,1999; Maubert, et al., 1999; Ricke, et al., 2000). This was 
suggested also by O'Neil-Dunne, et al., (2001), who reported that multigravid women 
begin producing significant anti-adhesion antibodies during the fourth month of 
 III
gestation, whereas primigravidae do not begin producing these antibodies until around 6 
months. On the other hand, Bull, et al., (1998) claimed that disease protection is 
dependent on a variant-specific immune protection directed against a variety of members 
of the PfEMP1 family.   
An important finding from the present study is that it demonstrated that there was clear 
association between antibody levels and age in pregnant women, (Table 3) that the 
percentage of the positive cases in the age group of less than 21 years old is only half the 
percentages in age groups of 21-30 and that of 31-40 years old. This could be another 
manifestation supporting the findings of Oralee, et al., (2000), who suggested that the 
anti- MSP1-19 antibody response develops with age, consequently he suggested that an 
anti-malaria vaccine strategy for pregnant mothers could delay infants first parasitemias 
until they are more capable of mounting a favorable anti- MSP1-19  response.  
In conclusion: low anti- MSP1-19 could be a possible explanation for the increased 
pregnancy -associated malaria in pregnant women especially primigravidae.  
Large scales longitudinal studies are needed to elucidate the role of reduce anti-malaria 
antibodies in the increased frequency of malaria attacks in pregnant women. 
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Figure 1: The epitope of MSP-119 of Plasmodium falciparum  
 
 
 
 
 
 
 
 
 
 
The epitope of MSP-119 of Plasmodium falciparum is  recognised by a specific 
monoclonal antibody. MSP-119 is shown in blue with the epitope indicated in red. The 
antibody is shown in green). 
 
 
 
 
 
                                 
 
 Table A: Common Malaria parasite antigens: 
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ANTIGEN DISEASE PHASE 
FOUND IN 
LOCATION IMMUNE RESPONSE 
   
Circumsporozoite 
protein (CS or CSP) 
  
Pre-erythrocytic 
  
Main sporozoite coat 
protein 
Central area of repeat 
sequences. Promotes strong B-
cell response that produces 
Abs that block sporozoites in 
culture. Induces CD8+ and 
CD4+ CTL response in mice.  
Sporozoite surface 
protein 2 (SSP2) 
 Pre-erythrocytic  Found on sporozoites of 
P. yoeli 
Mice immunized with CS and 
SSP2 expressing cells were 
protected by CD8+ CTLs.  
Liver stage-specific 
antigen 1 (LSA- 1) 
Pre-erythrocytic Infected liver cells 17 A.A. repeat causes CTL 
response in Africans that gave 
protection to severe malaria.  
Glycoproteins 
released during 
schizont rupture 
Pre-erythrocytic Released by the destruction 
of infected hepatocyte 
Induces the release of TNF 
which may cause malaria 
related illness.  
  Merozoite surface 
protein 1 (MSP-1 or 
MSA- 1) 
Erythrocytic  Major surface antigen of 
merozoites 
195-kDa protein breaks down 
to 19-kDa. Abs to 19-kDA 
reduces efficiency erythrocyte 
invasion.  
Merozoite surface 
protein 2 (MSP-2 or 
MSA- 2) 
  
Erythrocytic 
Second merozoite surface 
antigen unrelated to MSP-1. 
Has variable interior repeat 
region, but N and C ends are 
conserved. No immunogenicity 
known. 
Erythrocyte binding 
antigen 175 (EBA- 
175) 
Erythrocytic Surface of merozoites. 
Thought to be involved in 
attaching merozoite to 
erythrocyte. 
Immunizing rabbits with this 
protein can give blocking 
effect to merozoite invasion.  
Ring-infected 
erythrocyte surface 
antigen (RESA) 
Erythrocytic  Expressed on erythrocytes 
infected with ring stage 
parasites. 
Causes humoral immune 
response. In vitro RESA 
inhibits IL-2 levels. Evidence 
of intrauterine protection 
passed to fetuses via this Ag. 
vitro RESA inhibits IL-2 levels. 
Serine repeat 
antigen (SERA) 
Erythrocytic Antigen on merozoite 
involved with binding to 
the erythrocyte.  
Monkeys immunized with 
SERA and Freund’s adjuvant 
had high Ab titers to SERA 
 XIX
and resistance to P. falciparum.  
Glycophorin 
binding protein 
(GBP- 130) 
Erythrocytic Merozoite Causes humoral immune 
response in rhesus monkeys, 
but this immunity is not 
transferable with the monkey’s 
serum.  
Apical merozoite 
antigen (AMA- 1) 
Erythrocytic Apical region of the 
merozoite. May be involved 
in erythrocyte invasion.  
Known to stimulate humoral 
response in patients with 
chronic malaria. Also seems to 
stimulate T-cell response in 
vitro. 
Histidine rich 
protein 2 (HRP- 2) 
Erythrocytic Merozoite Humoral response used to test 
presence of merozoites in 
patient’s bloodstream.  
Rhoptry-associated 
proteins (RAP-1 
and RAP-2) 
Erythrocytic Associated with the apical 
region of the merozoite. 
Cause T-cell proliferation, and 
are involved in upregulating 
IL-6 and TNF production. 
Immunization with these 
proteins inhibits parasite 
growth in monkeys.  
Erythrocyte 
membrane proteins 
1 (PfEMP1) 
Erythrocytic Infected erythrocytes Involved in sequestration of 
infected erythrocytes.  
Sequestrin Erythrocytic Infected erythrocytes Ligand for CD36, a 
recognition protein expressed 
by vascular epithelium.  
Pfs25 Transmission Surface of P. falciparum 
zygotes and ookinetes 
Can block development of 
sexual stages and sporozoite 
development.  
 
 
